Edwards Lifesciences Reports Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Edwards Lifesciences (EW) PT Raised to $122 at Oppenheimer
October 28, 2021 7:46 AM EDTOppenheimer analyst Suraj Kalia raised the price target on Edwards Lifesciences (NYSE: EW) to $122.00 (from $120.00) while maintaining an Outperform rating.
The analyst commented, "Edwards reported 3Q21 revenues of $1.31B, slightly behind our/consensus' $1.34B/$1.32B estimates, but within guidance of $1.291.37B. TAVR... More
Edwards Lifesciences (EW) PT Raised to $129 at Stifel
October 28, 2021 6:42 AM EDTStifel analyst Rick Wise raised the price target on Edwards Lifesciences (NYSE: EW) to $129.00 (from $120.00) while maintaining a Buy rating.
The analyst commented, "Despite pockets of OUS TAVR strength/recovery, US Covid impacts pushed 3Q21 revenues to $1.31B, just below Street... More
Edwards Lifesciences (EW) Reports In-Line Q3 EPS
October 27, 2021 4:17 PM EDTEdwards Lifesciences (NYSE: EW) reported Q3 EPS of $0.54, in-line with the analyst estimate of $0.54. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.33 billion.
GUIDANCE:
Edwards Lifesciences sees Q4 2021 EPS of $0.53-$0.59, versus the consensus of $0.56.... More
